Disruption of the Lcn2 gene in mice suppresses primary mammary tumor formation but does not decrease lung metastasis

Proceedings of the National Academy of Sciences of the United States of America

Volumn 107, Issue 7, 2010, Pages 2995-3000

  Berger, Thorsten ^a   Cheung, Carol C ^a,b   Elia, Andrew J ^a   Mak, Tak W ^a  

^a PRINCESS MARGARET HOSPITAL   (Canada)

^b UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

Breast cancer; Lipocalin 2; Matrix metalloproteinase 9; Mouse mammary tumor virus polyoma middle T antigen

Indexed keywords

GELATINASE B; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; VIRUS MIDDLE T ANTIGEN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CANCER; BREAST CARCINOGENESIS; CANCER GROWTH; CANCER INHIBITION; CANCER SIZE; CONTROLLED STUDY; ENZYME ACTIVITY; FEMALE; GENE DISRUPTION; GENE TARGETING; LUNG METASTASIS; METASTASIS POTENTIAL; MOLECULAR GENETICS; MOUSE; MOUSE MAMMARY TUMOR ONCOVIRUS; NONHUMAN; PRIMARY TUMOR; PRIORITY JOURNAL;

ACUTE-PHASE PROTEINS; ANIMALS; BLOTTING, WESTERN; CROSSES, GENETIC; ELECTROPHORESIS, POLYACRYLAMIDE GEL; FEMALE; HISTOLOGICAL TECHNIQUES; LIPOCALINS; LUNG NEOPLASMS; MAMMARY NEOPLASMS, ANIMAL; MATRIX METALLOPROTEINASE 9; MICE; MICE, TRANSGENIC; NEOPLASM METASTASIS; ONCOGENE PROTEINS;

ANIMALIA; MOUSE MAMMARY TUMOR VIRUS; MUS; MUS MUSCULUS;

EID: 77649268223     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1000101107     Document Type: Article

References (28)

1. Flower DR, North AC, Sansom CE (2000) The lipocalin protein family: Structural and sequence overview. Biochim Biophys Acta 1482:9-24.
2. Akerstrom B, Flower DR, Salier JP (2000) Lipocalins: Unity in diversity. Biochim Biophys Acta 1482:1-8.
3. Triebel S, Blaser J, Reinke H, Tschesche H (1992) A 25 kDa α 2-microglobulin-related protein is a component of the 125 kDa form of human gelatinase. FEBS Lett 314: 386-388.
4. Kjeldsen L, Johnsen AH, Sengelov H, Borregaard N (1993) Isolation and primary structure of NGAL, a novel protein associated with human neutrophil gelatinase. J Biol Chem 268:10425-10432.
5. Goetz DH, et al. (2002) The neutrophil lipocalin NGAL is a bacteriostatic agent that interferes with siderophore-mediated iron acquisition. Mol Cell 10:1033-1043.
6. Berger T, et al. (2006) Lipocalin 2-de.cient mice exhibit increased sensitivity to Escherichia coli infection but not to ischemia-reperfusion injury. Proc Natl Acad Sci USA 103:1834-1839.
7. Stoesz SP, et al. (1998) Heterogeneous expression of the lipocalin NGAL in primary breast cancers. Int J Cancer 79:565-572.
8. Fernandez CA, et al. (2005) The matrix metalloproteinase-9/neutrophil gelatinase-associated lipocalin complex plays a role in breast tumor growth and is present in the urine of breast cancer patients. Clin Cancer Res 11:5390-5395.
9. Yan L, Borregaard N, Kjeldsen L, Moses MA (2001) The high molecular weight urinary matrix metalloproteinase (MMP) activity is a complex of gelatinase B/MMP-9 and neutrophil gelatinase-associated lipocalin (NGAL). Modulation of MMP-9 activity by NGAL. J Biol Chem 276:37258-37265.
10. Egeblad M, Werb Z (2002) New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2:161-174.
11. Yang J, et al. (2009) Lipocalin 2 promotes breast cancer progression. Proc Natl Acad Sci USA 106:3913-3918.
12. Guy CT, Cardiff RD, Muller WJ (1992) Induction of mammary tumors by expression of polyomavirus middle T oncogene: A transgenic mouse model for metastatic disease. Mol Cell Biol 12:954-961.
13. Dankort DL, Muller WJ (2000) Signal transduction in mammary tumorigenesis: A transgenic perspective. Oncogene 19:1038-1044.
14. Ichaso N, Dilworth SM (2001) Cell transformation by the middle T-antigen of polyoma virus. Oncogene 20:7908-7916.
15. Dilworth SM (2002) Polyoma virus middle T antigen and its role in identifying cancerrelated molecules. Nat Rev Cancer 2:951-956.
16. Qiu TH, et al. (2004) Global expression profiling identi.es signatures of tumor virulence inMMTV-PyMT-transgenicmice: Correlation to human disease. Cancer Res 64:5973-5981.
17. Lin EY, et al. (2003) Progression to malignancy in the polyoma middle T oncoprotein mouse breast cancer model provides a reliable model for human diseases. Am J Pathol 163:2113-2126.
18. Maglione JE, et al. (2001) Transgenic polyoma middle-T mice model premalignant mammary disease. Cancer Res 61:8298-8305.
19. Shi H, et al. (2008) Lipocalin 2 promotes lung metastasis of murine breast cancer cells. J Exp Clin Cancer Res 27:83.
20. Martin MD, et al. (2008) Effect of ablation or inhibition of stromal matrix metalloproteinase-9 on lungmetastasis in a breast cancermodel is dependent on genetic background. Cancer Res 68:6251-6259.
21. Hennighausen L, Robinson GW (1998) Think globally, act locally: The making of a mouse mammary gland. Genes Dev 12:449-455.
22. Cardiff RD, et al. (2000) The mammary pathology of genetically engineered mice: The consensus report and recommendations from the Annapolis meeting. Oncogene 19: 968-988.
23. Kubben FJ, et al. (2007) Clinical evidence for a protective role of lipocalin-2 against MMP-9 autodegradation and the impact for gastric cancer. Eur J Cancer 43:1869-1876.
24. Williams TM, et al. (2004) Caveolin-1 gene disruption promotes mammary tumorigenesis and dramatically enhances lung metastasis in vivo. Role of Cav-1 in cell invasiveness and matrix metalloproteinase (MMP-2/9) secretion. J Biol Chem 279:51630-51646.
25. Fantozzi A, Christofori G (2006) Mouse models of breast cancer metastasis. Breast Cancer Res 8:212.
26. Bauer M, et al. (2008) Neutrophil gelatinase-associated lipocalin (NGAL) is a predictor of poor prognosis in human primary breast cancer. Breast Cancer Res Treat 108:389-397.
27. Tomayko MM, Reynolds CP (1989) Determination of subcutaneous tumor size in athymic (nude) mice. Cancer Chemother Pharmacol 24:148-154.
28. Leng X, et al. (2009) Inhibition of lipocalin 2 impairs breast tumorigenesis and metastasis. Cancer Res 69:8579-8584.